GRI Bio (GRI) Cash & Equivalents (2020 - 2026)

GRI Bio's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $11.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 236.73% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $11.0 million (up 236.73% YoY), while the FY2025 annual figure was $8.2 million, up 63.66% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $11.0 million, up from $8.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $11.0 million in Q1 2026, with the low at $9000.0 in Q4 2022.
• The 5-year median for Cash & Equivalents is $4.7 million (2022), against an average of $4.5 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 99.76% in 2022, then jumped 19988.89% in 2023.
• GRI Bio's Cash & Equivalents stood at $9000.0 in 2022, then surged by 19988.89% to $1.8 million in 2023, then soared by 178.1% to $5.0 million in 2024, then jumped by 63.66% to $8.2 million in 2025, then surged by 34.26% to $11.0 million in 2026.
• Business Quant data shows GRI's Cash & Equivalents at $11.0 million in Q1 2026, $8.2 million in Q4 2025, and $4.1 million in Q3 2025.